幽门螺杆菌感染与反流性食管炎及Barrett食管的相关性

目的 探讨幽门螺杆菌的根除与反流性食管炎(RE)及Barrett食管(BE)的相关性及临床意义.方法 262例患者(RE177例、BE 85例)分为无幽门螺杆菌感染组139例(A组),有幽门螺杆菌感染组123例(B组);B组又随机分成2个亚组,B1组62例,B2组61例.A组及B1组给予洛赛克20 mg/次,2次/d,多潘立酮10 mg/次,3次/d,果胶铋100 mg/次,3次/d,疗程为8周;B2组在A组、B1组治疗方法的基础上加用阿莫西林500 mg/次,2次/d,克拉霉素500 mg/次,2次/d或替硝唑500 mg/次,2;A/d,其中三种抗生素选两种,应用2周.治疗前及治疗后行内镜、病理及24 h食管pH及胆红素监测检查.结果 治疗后3组患者症状改善总有效率均达95.0%以上[分别为A组97.8%(136/139)、B1组96.8%(60/62)、B2组98.4%(60/61)],与治疗前比较差异有统计学意义(P<0.05),但3组间比较,差异无统计学意义(P>0.05);内镜下3组反流性食管炎患者总有效率分别为92.9%(78/84)、91.8%(45/49)、88.6%(39/44),差异有统计学意义(P<0.05),Barrett食管患者未见明显效果,有效率约35.0%,与治疗前比较差异无统计学意义(P均>0.05);3组患者24 h食管pH及胆红素监测与治疗前比较均有显著改善(P<0.05),但3组间比较无明显差异(P>0.05).结论 幽门螺旋杆菌感染的RE及BE患者,可进行抗HP治疗但须同时进行抑制胃酸减少胃液,促进胃排空及保护食道黏膜的系统治疗,短期内可有效预防RE及BE的进展,长期效果还有待长期、大量的临床病例观察.

Association of helicobacter pylori infection with reflux esophagitis and Barrett esophgus

Objective To study the influence of anti-Helicobacter pylori therapy on reflux esophagitis (RE) and Barrett's esophagus (BE). Methods Two hundred and sixty-two patients including 177 patients with RE and 85 patients with BE were divided into 2 groups: Group A,139 patients without Hp infection;Group B,123 patients with Hp infection, which was further divided into 2 groups (group B1 and group B2) randomly. The pa-tients in group A and B1 were treated with Losec 20 mg bid, domperidone 10 mg tid and colloidal bismuth pectin 100 mg tid for 8 weeks, group B2 were treated with 2 kinds of antibiotics which were chosen from 3 types of antibiot-ics including amoxicillin 500 mg bid, Clarithromycin 500 mg bid or tinidazole 500 mg bid for 2 weeks additional to the same treatment as group A and B1. Endoscopy, pathologic examination, 24 h esophagus pH value and bilirubin were measured before and after treatment. Results The overall rates of improvement on symptoms in the 3 groups were 95.0% (group A: 97.8% (136/139), group B1: 96.8% (60/62), group B2: 98.4% (60/61)), which was significantly different from that before treatment (P < 0.05). However, the overall effect rates were not significantly different among the 3 groups (P > 0.05). The overall effect rate based on endoscopy examination in the RE patients 92.9% (78/84),91.8% (45/49) and 88.6% (39/44) in group A,B1 and B2,respectively,and the differences were statistically significant among the 3 groups (P <0.05). The overall effect rates in the BE patients were about 35.0%,which showed non-significant effect compared to that before treatment (P >0.05). 24 hrs esophagus PH value and bilirubin were significantly improved in the 3 groups (P < 0.05), whereas the difference among the 3 groups were not significant (P > 0.05). Conclusions RE and BE patients with HP infection could be treated with anti-Helicobacter pylori therapy. However, systematic therapy of anti gastric acid, prokinetics and mucosa protector must be performed simultaneously. This might be effective in preventing the development of RE and BE in short term. The long term effect is still uncertain and large scale, long term clinical studies are needed.